Dr. P.H. Andersen is Senior Vice President of External Relations & Corporate Patents at H. Lundbeck A/S. Lundbeck is a CNS focussed Pharmaceutical Company headquartered in Copenhagen, Denmark. He holds degrees in chemistry, biochemistry and medicine from University of Copenhagen. He was Executive Vice President of Research with Lundbeck R&D from 1999-2011. Prior to joining Lundbeck he was Vice President and Director of Drug Discovery in Acadia Pharmaceuticals and he held various positions at Novo Nordisk from 1983-1997.
Dr Andersen has been involved in the start-up of a number of biotech companies in Medicon Valley over the years. Currently, he is Chairman of the Board of Directors in Epitherapeutics Aps and Prexton Therapeutics SA. He is also Chair of the Research Directory Group in EFPIA and a member of the Innovative Medicine Initiative Governing Board.
Dr Mary BAKER
Dr Mary BAKER is President of the European Brain Council. She is immediate past President of the European Federation of Neurological Associations. Consultant to the World Health Organisation (WHO) and Chair of their Working Group on Parkinson's Disease, she also a Patron and Past President of the European Parkinson's Disease Association. Mary served as Chief Executive of the Parkinson's Disease Society of the United Kingdom for a period of 18 years.
Significant appointments include membership of the Council of the Association of the British Pharmaceutical Industry (ABPI), the ABPI Code of Practice, Director at Large for the World Stroke Association to name a few. An Honorary Doctor from the University of Surrey, Mary received the prestigious British Neuroscience Association Award for Outstanding Contribution to British Neuroscience and for Public Service in 2009. In 2012 she was appointed Visiting Fellow at the London School of Economics Health Centre and Associate Membership of the Health Services Research Unit, University of Oxford.
Richard BERGSTRÖM is the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) having been appointed in April 2011.
Previously he served for nine years as the Director-General of LIF, the Swedish Association of the Pharmaceutical Industry after holding positions in Switzerland in regulatory affairs at the pharmaceutical companies Roche and Novartis. Mr Bergström was also appointed by the Swedish Government to the Board of the Karolinska Institute. He is a pharmacist by training, receiving his MScPharm degree from the University of Uppsala, Sweden in 1988.
Colin BLAKEMORE, FMedSci, FRCP (Hon), FRSM (Hon), FSB (Hon), FRS, is Professor of Neuroscience and Philosophy at the University of London and Emeritus Professor of Neuroscience at Oxford. From 2003-7 he was Chief Executive of the Medical Research Council.
Colin studied Medical Sciences at Cambridge and completed a PhD at the University of California, Berkeley. After working for 11 years in Cambridge, he moved to Oxford in 1979 to become Waynflete Professor of Physiology and a Professorial Fellow of Magdalen College. His research has been concerned with many aspects of vision, early development of the brain, plasticity of the cerebral cortex and neurodegenerative disease.
He is President of the Motor Neurone Disease Association and Brain Tumour UK, and Vice-President of the Progressive Supranuclear Palsy Association. He has been President of the British Association for the Advancement of Science, the British Neuroscience Association, the Physiological Society and the Society of Biology. He is a frequent broadcaster on radio and television, and writes in the national press about science and science policy.
Dr Martin BRÜNE
Dr Martin BRÜNE is Professor of Psychiatry and Head of the Division of Cognitive Neuropsychiatry and Psychiatric Preventive Medicine at the LWL University-Hospital, Ruhr-University Bochum, Germany. His current clinically oriented research projects include the analysis of social cognition in psychosis in a wide range of areas. Having graduated in medicine in 1988, he went on to train in both neurology and psychiatry. Subsequent training included a Visiting Research Scientist Fellowship at the Centre for the Mind, a joint venture of the Australian National University and the University of Sydney.
Dr Brüne is author of more than 170 articles and book chapters and has written the Textbook of Evolutionary Psychiatry: The origins of Psychopathology. He brings his experience to several psychiatric and neuroscientific societies including Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), International Society for Human Ethology (ISHE), Gesellschaft für Anthropologie (GfA), and the International Graduate School of Neuroscience (IGSN), Ruhr-University Bochum.
Professor Fabien CALVO
Professor Fabien CALVO, MD, PhD is Deputy General Director of the National Cancer Institute of France (INCa) with responsibility for Research and Innovations Programmes and Director of the Cancer Multi-Organisational Institute of the French National Alliance for Life and Health Sciences (Aviesan). He is currently Professor of Pharmacology at the Denis Diderot Medical University in Paris.
As a resident and senior registrar in Paris hospitals and a research associate of the National Cancer Institute in the US, he specialised in oncology and haematology. This foundation helped him to build a strong research reputation. He has since been Director of the Clinical Investigation Centre in St Louis Hospital Paris and lead the unit in Inserm responsible for the identification of new molecular targets for the treatment of cancer from 1995 -2008. He has published more than 200 original and review articles.
To date, Prof Calvo has also headed the clinical research programmes in Cancer in the Paris area and worked as the coordinator for cancer mission for the Ministry of Research and higher Education from 2006-2007. He is currently a Board member of the post graduate school "oncogenesis fundamental basis".
Enda CONNOLLY is Chief Executive of the Health Research Board in Ireland. His main focus in this role has been to strategically position the organisation to deliver a step change in health research. His aim is to increase research capacity in the health services and create an environment that can absorb new innovations, deliver better service and improve patient care. In doing so, he believes we can create the perfect platform to attract healthcare industry to Ireland and, in turn, help develop the economy.
Prior to this, Enda spent more than 30 years in IDA Ireland, where he played a pivotal role in leading change, developing strategy, building stakeholder confidence and securing significant foreign direct investment. He was instrumental in developing the agency's Research and Development Strategy.
Enda continues to play an active role in various Government development bodies, including Enterprise Ireland's Industrial Research and Commercialisation Committee and the inter-agency Health Research Group. He is the national representative on both the Management Board and the Executive Board of the European Joint Programming initiative on Neurodegenerative Diseases.
Angela COULTER PhD, Hon FFPH, Hon FRCGP is Director of Global Initiatives at the Informed Medical Decisions Foundation, Boston, and Senior Research Scientist at the Department of Public Health, University of Oxford. Working as a health policy analyst and researcher, she specialises in patient and public involvement in healthcare. She is a Senior Visiting Fellow at the King's Fund in London and holds Honorary Fellowships at the UK Faculty of Public Health and the Royal College of General Practitioners and is a Trustee of National Voices.
Her success has led to the publication of more than 250 research papers and reports and several books. Her latest book, Engaging Patients in Healthcare, was published by Open University Press in August 2011 and was highly commended in the 2012 BMA awards. Her esteemed career is also reflected in her being awarded the 2012 Donabedian Foundation of Barcelona prestigious international award for her work on patient-centred care.
Dr Ruxandra DRAGHIA-AKLI
Dr Ruxandra DRAGHIA-AKLI (MD, PhD) is Director of the Health Directorate at the Research and Innovation DG of the European Commission. Dr Draghia-Akli served as Vice-President of Research at VGX Pharmaceuticals (now Inovio) and VGX Animal Health. Her research activities focused on molecular biology, gene therapy and vaccination. She is a global leader in the field of nucleic acid delivery for therapeutic and vaccination applications. She is an inventor on more than a hundred patents and patent applications.
Dr Draghia published numerous scientific papers and served as ad-hoc reviewer for granting agencies, meetings for gene therapy and endocrinology societies, and scientific journals in Europe and the USA.
Dr Draghia received an MD from Carol Davilla Medical School and a PhD in human genetics from the Romanian Academy of Medical Sciences. She also completed a doctoral fellowship at the University of Rene Descartes in Paris and a post-doctoral training at Baylor College of Medicine (BCM), Houston, Texas, USA, and served as faculty at BCM. In 2012, she became an honorary member of the Romanian Academy of Medical Sciences.
Giovanni B.FRISONI is a Clinical neurologist and Deputy Scientific Director of the National Alzheimer's Centre in Brescia, Italy where he leads the local Laboratory of Neuroimaging and Translational Care Unit. He is author of over 350 scientific papers listed in PubMed, imaging editor for Neurobiology of Aging, and founding editorial board member of The Lancet Neurology.
Frisoni is Principal Investigator of European Commission funded projects FP6 ENIR in 2006-7, FP7 neuGRID in 2008-10, FP7 outGRID in 2009-12, and FP7 neuGRID for users in 2011-14, aiming to develop an innovative working environment for imaging neuroscientists based on cloud computing. He has brought amyloid imaging to Italy with ISS "Relationship between 18-flutemetamol Amyloid imaging and post surgery delirium in elderly".
Frisoni has introduced ADNI to Europe with Alzheimer's Association grant Pilot European ADNI in 2005-6 and IMI Pharmacog WP5/EADNI in 2010-ongoing, and ADNI and DIAN to Italy with Italian Ministry of Health-funded Italian ADNI (2010-12) and Italian DIAN (2012-ongoing). He is leading the international Alzheimer's Association grant Harmonized Protocol for Hippocampal Volumetry (2010-ongoing) aiming to standardize the manual segmentation of the hippocampus globally. He has held the position of chairman of Alzheimer's Imaging Consortium at ICAD 2010 and 2011.
Máire GEOGHEGAN-QUINN is Commissioner for Research, Innovation and Science since 2010. Between 2000 and 2010, she served as a Member of the European Court of Auditors. From 1975 to 1997, she was a Member of the Irish parliament (Dáil Eireann). In 1979, she became the first woman to be appointed as a Cabinet Minister since the foundation of the Irish state, and served as Minister with responsibility for the Gaeltacht until 1981.
She has held various other ministerial posts, including Minister for European Union Affairs from 1987 to 1991, when she oversaw the preparation of the Irish presidency of the European Union in 1990; Minister for Tourism, Transport and Communications (1992-'93). She was the Irish Minister for Justice (1993-'94) and one of the negotiators of the Downing Street Declaration, which was signed between the Irish and British governments.
From 1997 to 2000, Máire Geoghegan-Quinn served as Non-Executive Director of both Aer Lingus and the Ryan Hotel Group. She has been a TV presenter and a columnist in the Irish Times newspaper, and is a former Member of the Governing Authority of the National University of Ireland Galway.
John GOLDING is President of the European Multiple Sclerosis Platform (EMSP) in 2010. He has been living with Multiple Sclerosis (MS) symptoms since 1982 and was diagnosed in 1987.
Originally from Tenerife, John was educated in Spain, England, Ireland and Norway and holds academic and profes¬sional qualifications in Business Administration, Marketing and many Modern Languages.
His professional background is primarily as a senior executive in the Motor Industry, but he also has had professional management experience in the NGO sector in Development Aid work at International level. Now retired from professional life, he continues to work as Business Consultant for several companies and until recently, held a number of non-executive directorships and Board appointments in a variety of organisations.
John sits on the board of the Multiple Sclerosis International Federation (MSIF) and is a member of the newly formed group "People with MS Advisory Committee" (PMSAC), who will advise the MSIF Board of Trustees on any issues related to the needs and aspirations of people with and affected by MS. He was Vice-President of EMSP 2006-2010 and of The Norwegian MS Society.
John was a passionate sportsman as a young man and excelled in rugby, cricket and athletics and he continues to have a great dedication and interest in all kinds of sport and enjoys music with a preference for the classics.
Martin HÄRTER, Dipl Psych MD PhD Professor of Medical Psychology is Director at the Department of Medical Psychology at the University Medical Center Eppendorf (UKE) in Hamburg. He received his MD (1991) and his PhD (1993) in Psychology at the University of Freiburg. He is a licensed psychotherapist since 2000. His main research interests are in somato-psychological comorbidity, epidemiology of mental disorders, patient involvement and shared decision-making as well as in health services research in general.
He coordinated the German National Clinical Practice Guideline for Depression from 2005-2009 and is member of the expert panel of the German National Cancer Plan since 2008. He is spokesman of the Center for Health Care Research (chcr) at the UKE and of "psychenet – the Hamburg Network for Mental Health".
Richard HUGHES, MD FRCP FMedSci, is President of the European Federation of Neurological Societies, Emeritus Professor of Neurology at King's College London and Honorary Professor University College London. Trained at Clare College, Cambridge, Guy's Hospital and the National Hospital, Queen Square, London, he was Consultant Neurologist at Guy's Hospital, London, from 1975 until his retirement in 2007. His research interests include the cause and treatment of inflammatory neuropathy, especially Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. He has led several randomised controlled trials investigating the value of immunotherapy for both these diseases.
In 1999 Professor Hughes founded the Cochrane Neuromuscular Review Group, remained its Chief Editor until 2008 and still serves on its editorial Board. He was the President of the international Peripheral Nerve Society and the founding chair of its special interest group the Inflammatory Neuropathy Consortium.
Dr Jackie HUNTER
Dr Jackie HUNTER is a co-founder of OI Pharma Partners Ltd. As a senior leader in the Pharmaceutical industry for more than 25 years, she has recently become widely recognised as an expert in the application of open innovation in healthcare. Her company helps Life Sciences companies apply open innovation principles effectively in their businesses. She built a strong research and development reputation at GlaxoSmithKline, where she was responsible for clinical and non-clinical portfolios, and focused primarily in the neuroscience therapeutic area, taking compounds from early research to late-phase development.
Her combination of international industry experience and academic collaborations has led to positions on Board of large private initiatives such as the Innovative Medicines initiative as well as a variety of other academic and industry advisory boards and committees for funding agencies and charities. Her reputation has given rise to several awards including Women of achievement in Science, Engineering and Technology and a CBE for services to the pharmaceutical industry.
Her own experience of having a parent with dementia has made her more passionate about ensuring the effective translation of basic research in neuroscience into effective therapeutics and facilitating new models of engagement between industry and academia.
Marian JOËLS is Professor in Neuroscience at the University Medical Center Utrecht / Utrecht University and Director of the Rudolf Magnus Institute. Her research focuses on the effects of stress on the brain, particularly at the level of cells and circuits, but also touching the underlying molecular mechanism and the functional relevance, in rodents as well as humans. She is particularly interested in the lasting effects of stress early in life, as a risk factor for the development of psychopathology.
Having studied biology at the University of Amsterdam, she went on to attain her PhD in Utrecht and conducted postdoctoral research in the USA. Between 1991 and 2009 she worked at the University of Amsterdam. She is currently President of the Federation of European Neuroscience Societies and is a member of the Royal Netherlands Academy of Arts and Sciences since 2002.
Richard A. JOHNSON
Richard A. JOHNSON is CEO, Global Helix LLC, Washington DC and National Academy of Sciences, Board on Life Sciences. Global Helix LLC, a thought leadership and strategic positioning consulting firm, founded by Richard, which focuses on enabling basic research and entrepreneurship rethinking STEM policymaking, linking research to innovation and value creation in new ways, and assessing emerging policy issues for universities and firms. His expertise covers several converging domains for knowledge-based economies, including synthetic biology and emerging life sciences, neuroscience and the brain, Big Data, healthy aging and Alzheimer's, and core platform technologies. He has a Juris doctorate degree from Yale, an MS from Massachusetts and an undergraduate degree from Brown University.
Richard's vast experience has led to his involvement in numerous Boards, Committees, Advisory groups and several U.S. university-industry task forces. These include being a member of the Board on Life Sciences at the US National Academy of Sciences (NAS) and many of their committees, Chairman of the OECD/BIAC Science & Technology Committee, a member of the EU's Healthy Brain initiative, the Brown Institute on Brain Science, the US Brain Activity Map project.
Patrick J. KENNEDY
Patrick J. KENNEDY is Former Congressman for Rhode Island and co-founder of One Mind for Research, an independent, non-partisan, non-profit organization dedicated to curing the diseases of the brain and eliminating the stigma and discrimination associated with mental illness and brain injuries. One Mind™ sponsors ground breaking new research and creates portals to shared scientific data, leading to improved diagnostics, more effective treatment, and, ultimately, cures for all types of mental illness and brain injury.
Kennedy, who has openly discussed his struggles with depression and bipolar disorder, had already brought his passion for mental health research and advocacy into the spotlight when he co-authored and was the lead sponsor of the Mental Health Parity and Addiction Equity Act. This legislation, which was the largest he and his father worked on together, provides tens of millions of Americans who were previously denied care with access to mental health treatment.
In addition to his work with One Mind for Research, he is an active board member of Best Buddies, Research America, and the Edward M. Kennedy Institute. He sits on the council for the National Institute on Drug Abuse, as well as the advisory council for Faces & Voices of Recovery.
He is a tireless advocate for mental health treatment, research and the elimination of the stigma associated with mental illness. He has been recognized for his advocacy with honors and awards from many organizations including the National Council, Peter C. Alderman Foundation, Clifford Beers Clinic, The JED Foundation, Sarah Jane Brain Foundation and Minding Your Mind.
Dr Ingrid KLINGMANN
Dr Ingrid KLINGMANN MD, PhD, FFPM, FBCPM is owner of PHARMAPLEX bvba, a pharmaceutical development and site management support consulting company in Brussels.
Having specialized in General Medicine, Clinical Pharmacology and Pharmaceutical Medicine, she joined the pharmaceutical industry as medical advisor. She held senior management positions in different international contract research organisations and was responsible for operational, scientific, regulatory and business aspects of international clinical research projects from Phase I to Phase IV. She also spent four years she as CEO of two investigative sites in London, performing clinical trials in acute and chronic pain as well as musculo-skeletal diseases.
Dr Klingmann is Chairman of the Board of the European Forum for Good Clinical Practice (EFGCP) as well as Co-Chair of the EGAN/EFGCP Working Party "Patients' Roadmap to Treatment". On behalf of EFGCP she had lead or co-ordinated a variety of Work Packages including the PatientPartner Project, the Innovative Medicines Initiative project, PharmaTrain, and the European Patients Academy on Therapeutic Innovation EUPATI.
She chairs the clinical research module of the post-graduate Master in Regulatory Affairs course at the University of Bonn, Germany, and co-chairs the Diploma Course in Clinical Trial Practices at the University of Basel, Switzerland.
Dr Juan LERMA
Dr Juan LERMA is Professor at the Spanish Research Council. His specialty is the molecular basis for neuronal communication. His work focuses on the most important signalling system in the brain: glutamate and its receptors, which support fundamental physiological activities and which can trigger brain disease when they are deregulated.
Dr Lerma holds a variety of positions including, Director of Instituto de Neurociencias, CSIC-UMH; President of the Spanish Society for Neuroscience (SENC); Chair of the West Europe Regional Committee of the International Brain Research Organization (IBRO). He is also a member of the European Molecular Biology Organization (EMBO); the European DANA Alliance for the Brain (EDAB) and the Academia Europaea. He sits on the editorial board of Neuron, Neuroscience, Frontiers in Neuroscience and Neuroscience Bulletin.
His success is reflected in the number of awards he has received, including the Health Science Foundation Award; the Santiago Grisolía Chair Award; the Award "Gabriel Alonso de Herrera" to the Excellence; the "Fundación CEOE" Science Award; and the "Alberto Sols" Award for Career Achievements.
Ms Kathleen LYNCH
Ms Kathleen LYNCH is the Irish Minister of State at the Department of Health and Department of Justice, Equality and Defence with responsibility for Disability, Equality, Mental Health and Older People.
Appointed Minister of State in March 2011, she is accountable for developing and articulating Government policy on Disability, Equality, Mental Health and Older People. Minister Lynch is leading a fundamental Mental Health Reform Programme in Ireland (Vision for Change).
In 1994 Minister Lynch was first elected to the Irish Parliament (Dáil Eireann) for the Labour Party. She was subsequently elected again in 2002 and has retained her seat since. In March 2011 the Labour Party formed a new coalition government with the Fine Gael Party with an agreed programme for government, including major Health Care Reform. Until her appointment she was a full-time Public Representative. She has been a member of the Joint Parliamentary Committees on Health (2007), Justice, Equality, Defence and Women's Rights (2002-2007) and Enterprise and Small Business (2002 – 2006).
Professor Adriana MAGGI
Professor Adriana MAGGI is the Director of the Centre of Excellence for Neurodegenerative Diseases and Professor of Pharmacology and Biotechnology at the University of Milan. She currently leads a group of 20 researchers who are funded primarily by International organisations such as the European Commission and the US National Institutes of Health as well as Pharmaceutical companies. She is author of 150 papers and scientific reviews and has authored, or edited, four books and been granted five patents. Prof Maggi is a recent recipient of an ERC Advanced grant (2013 -2018).
Her distinguished career is reflected by her representation on a wide variety of Boards and working groups. Most recent positions include Vice-President of the Management Board of the EU Joint Programme in Neurodegenerative Diseases, a Member of the Council of the European Society for Molecular Medicine and a member of the Scientific Board for the European Medicines initiative of the EC.
Isabel de la MATA
Isabel de la MATA is currently Principal Adviser for Public Health at Directorate SANCO – Health & Consumers. She is a graduate in Medicine at the University of Basque Country in 1983 and holds post-graduate degrees from the University of Leuven and Paris VI. She is specialist in Preventive Medicine and Public Health.
She worked at the Ministry of Health of Spain and at the Regional Departments of Health in the Basque Country and in Madrid. She has an experience working with International Organisations, such as the WHO, Pan American Health Organisation and Inter-American Development Bank. From 2004 until February 2008 she worked at the Permanent Representation of Spain to the EU.
Pedro Manuel Palma Leal Ortiz de MONTELLANO
Pedro Manuel Palma Leal Ortiz de MONTELLANO is currently the President of GAMIAN Europe – Global Alliance of Mental Illness Advocacy Networks-Europe, after being the treasurer and a board member for some years. He has been working in an Assets Management Company in Lisbon, Portugal, since 2012.
He received a degree in agronomics engineering from the Lisbon Institute of Agronomics and did postgraduate work at the Institute of Economics and Management, receiving a Master's degree in real estate management and valuation. At the age of 23, he was diagnosed with bipolar disorder.
As a volunteer, Mr Montellano was President of the Fiscal Board of the Portuguese Association for the support of Depressive and Bipolar patients (ADEB) from 2001-2004 and served as Treasurer until 2012. He has also volunteered as a children's rugby coach for many years.
Professor Charles NORMAND
Professor Charles NORMAND is the Edward Kennedy Professor of Health Policy and Management at Trinity College Dublin. A trained economist, he has worked for 25 years on the economics of health and healthcare. His research is mainly on health care finance, equity and access to services, management of chronic diseases, screening policies and end of life care. He has a particular interest in understanding the ways in which ageing impacts on use of health and social care, and on financing of services for older people.
He has published extensively and is a co-author of a leading textbook on health economics and the WHO guidebook on social health insurance. He is co-principal investigator on the Irish Longitudinal Study on Ageing (TILDA). Prof Normand is also Vice-Chairman of St James's Hospital Dublin and Chair of the WHO European Observatory on Health Systems and Policy.
Professor Luca PANI
Professor Luca PANI is a Medical Doctor, specialising in Psychiatry, Pharmacology and Molecular Biology. He is currently Director General of the Italian Medicines Agency (AIFA).
Prof Pani's professional trajectory has touched several areas of expertise, in addition to his commitment to teaching and clinical activity. These include national and international regulatory activities for the European Union; preparation, evaluation and coordination of Research Projects; Strategic Planning and partnerships with national and international Research Groups; participation in international bodies and Advisory Committees. He is the author of over one hundred scientific publications and the author and editor of several volumes. He is Italian Alternate Permanent Member of the Committee for Human Medicine Products (CHMP); Elected Member of the Working Party on Central Nervous System (WP-CNS) and of the Scientific Advice Working Party (SA-WP) of the European Medicines Agency (EMA) in London (UK). Prof Pani is also Director of Research of the Italian National Research Council and Voluntary Professor at the University of Miami, Florida.
Dr James REILLY
Dr James REILLY is the Irish Minister for Health. He is politically accountable for developing and articulating Government policy on health and personal social services, and for the overall performance of the health service. Areas of responsibility include support for children and families, primary care, cancer control, acute hospitals, disability and mental health, care of older people.
In 2007 Dr Reilly was elected to Dáil Éireann, the Irish parliament, for the Fine Gael Party, and was appointed party spokesperson on Health. In July 2010 he became Deputy Leader of his party. He became Minister for Health in March 2011 when the Fine Gael party formed a new coalition government with the Labour party.
Dr Reilly has worked as a General Practitioner in the Dublin area for the past 25 years. He is a former President of the Irish Medical Organisation (IMO) and has also served as Chairman of the General Practitioner Committee. He was the IMO representative for the World Medical Association. He is a member of the Royal College of General Practitioners and the Irish College of General Practitioners.
Andreas ROEPSTORFF is Professor in Cognition, Communication and Culture at Department of Culture and Society and at Department of Clinical Medicine, Aarhus University, Denmark.
Trained in social anthropology and in neurobiology, he has published within these disciplines as well as in transdisciplinary collaborations across other fields (e.g., psychology, clinical medicine, linguistics, and philosophy). He works at the interface between anthropology, cognitive science and neuroscience, equally interested in the workings of the mind and brain, and in how cognitive science and brain imaging, as fields of knowledge production, relate to other scientific and public fields. He is the director of the Interacting Minds Centre and co-director at MINDlab at Aarhus University.
Professor André SYROTA
Professor André SYROTA is Chairman and CEO of the French Institute for Health and Medical Research (Inserm) and President of the French National Alliance for Life and Health Sciences (Aviesan). He is a professor of medicine and specialises in the development of non-invasive functional imaging methods in humans. His research has given rise to some 200 publications.
In addition to a demanding role at Inserm, he presides over Aviesan which was founded in 2009 by a variety of French Research organisations. The group aims to ensure national strategic and programme co-ordination of life and health science research, boost potential and increase visibility of research at national and international levels and ensure research was seen as responsive to scientific questions or fundamental health problems. Since October 2011, Prof Syrota has also been one of the Vice- Presidents of Science Europe.